Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET

被引:18
作者
Coppola, Antonio [1 ]
Castaman, Giancarlo [2 ]
Santoro, Rita C. [3 ]
Mancuso, Maria Elisa [4 ]
Franchini, Massimo [5 ]
Marino, Renato [6 ]
Rivolta, Gianna Franca [1 ]
Santoro, Cristina [7 ]
Zanon, Ezio [8 ]
Sciacovelli, Laura [9 ,10 ]
Manca, Salvatore [11 ,12 ]
Lubrano, Riccardo [13 ,14 ]
Golato, Maria [15 ,16 ]
Tripodi, Armando [17 ,18 ,19 ]
Rocino, Angiola [20 ,21 ]
机构
[1] Univ Hosp Parma, Reg Reference Ctr Inherited Bleeding Disorders, Via Gramsci 14, I-43126 Parma, Italy
[2] Careggi Univ Hosp, Dept Oncol, Ctr Bleeding Disorders & Coagulat, Florence, Italy
[3] Pugliese Ciaccio Hosp, Ctr Haemorrhag & Thrombot Disorders, Catanzaro, Italy
[4] Humanitas Clin & Res Ctr IRCCS, Ctr Thrombot & Haemorrhag Dis, Rozzano, Italy
[5] Carlo Poma Hosp, Dept Haematol & Transfus Med, Mantua, Italy
[6] Univ Hosp Bari, Haemophilia & Thrombosis Ctr, Bari, Italy
[7] Umberto I Univ Hosp, Haematol, Rome, Italy
[8] Univ Hosp Padua, Haemophilia Ctr, Padua, Italy
[9] Univ Hosp Padua, SIBioC, Padua, Italy
[10] Univ Hosp Padua, Dept Lab Med, Padua, Italy
[11] San Martino Hosp, SIMEU, Oristano, Italy
[12] San Martino Hosp, Dept Emergency Med & Intens Care, Oristano, Italy
[13] Sapienza Univ Rome, SIMEUP, Rome, Italy
[14] Sapienza Univ Rome, Dept Paediat, Unit Paediat Nephrol, Rome, Italy
[15] SS Annunziata Univ Hosp, ASL Lanciano Vasto Chieti, SIPMeL, Chieti, Italy
[16] SS Annunziata Univ Hosp, ASL Lanciano Vasto Chieti, Unit Clin Pathol, Chieti, Italy
[17] Osped Maggiore Policlin Fdn, Angelo Bianchi Bonomi Haemophilia & Thrombosis Ct, SISET, Milan, Italy
[18] Osped Maggiore Policlin Fdn, Angelo Bianchi Bonomi Haemophilia & Thrombosis Ct, IRCCS Ca Granda, Milan, Italy
[19] Luigi Villa Fdn, Milan, Italy
[20] Osped Mare, ASL Napoli Ctr 1, AICE, Naples, Italy
[21] Osped Mare, ASL Napoli Ctr 1, Haemophilia & Thrombosis Ctr, Haematol, Naples, Italy
关键词
bleeding; emergency; emicizumab; FVIII; haemophilia A; surgery; BISPECIFIC ANTIBODY;
D O I
10.1111/hae.14172
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction The factor VIII (FVIII)-mimetic bispecific monoclonal antibody, emicizumab, previously approved for prophylaxis in haemophilia A with inhibitors, has been recently licensed in several countries also in patients with severe haemophilia A (PWSHA) without inhibitors. The introduction of this innovative agent requires the development of specific pathways at Haemophilia Treatment Centres (HTC), particularly regarding laboratory testing and treatment of breakthrough bleeds and invasive procedures/surgeries, even more critical when patients are managed by non-specialist professionals. Limited literature data and clinical experience in PWSHA without inhibitors on emicizumab are currently available. Aim To promote awareness and overcome these challenges, the Italian Association of Haemophilia Centres (AICE) issued a guidance on the management of PWSHA without inhibitors on emicizumab prophylaxis, focused on emergency and shared with other National Scientific Societies in the field. Methods The document, drafted by an AICE expert panel and approved through online consultation, was further revised by a multidisciplinary working group, including members of 5 haemostasis, laboratory and emergency scientific societies. The final version was approved by the Council of each society. Results General recommendations about use of FVIII concentrates for the treatment of bleeding or haemostatic coverage of invasive procedures/surgeries and laboratory monitoring in PWSHA without inhibitors on emicizumab are provided. Specific issues of the management in the emergency room are focused, highlighting the need for direct involvement or formalized supervision by specialist HTC physicians. Conclusions This guidance provides a reference pathway to be implemented in the different healthcare organizations, especially for the challenging emergency management in this setting.
引用
收藏
页码:937 / 945
页数:9
相关论文
共 26 条
  • [1] Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays
    Adamkewicz, Joanne, I
    Chen, David C.
    Paz-Priel, Ido
    [J]. THROMBOSIS AND HAEMOSTASIS, 2019, 119 (07) : 1084 - 1093
  • [2] Agenzia Italiana del Farmaco, 2020, GAZZETTA UFFICIALE G, P26
  • [3] Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET
    Castaman, Giancarlo
    Santoro, Cristina
    Coppola, Antonio
    Mancuso, Maria E.
    Santoro, Rita C.
    Bernardini, Sergio
    Pugliese, Francesco R.
    Lubrano, Riccardo
    Golato, Maria
    Tripodi, Armando
    Rocino, Angiola
    Santagostino, Elena
    [J]. BLOOD TRANSFUSION, 2020, 18 (02) : 143 - 151
  • [4] Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee
    Collins, P. W.
    Liesner, R.
    Makris, M.
    Talks, K.
    Chowdary, P.
    Chalmers, E.
    Hall, G.
    Riddell, A.
    Percy, C. L.
    Hay, C. R.
    Hart, D. P.
    [J]. HAEMOPHILIA, 2018, 24 (03) : 344 - 347
  • [5] Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors
    Ebbert, Patrick T.
    Xavier, Frederico
    Seaman, Craig D.
    Ragni, Margaret V.
    [J]. HAEMOPHILIA, 2020, 26 (01) : 41 - 46
  • [6] A hemophilia A mouse model for the in vivo assessment of emicizumab function
    Ferriere, Stephen
    Peyron, Ivan
    Christophe, Olivier D.
    Kawecki, Charlotte
    Casari, Caterina
    Muczynski, Vincent
    Nathwani, Amit
    Kauskot, Alexandre
    Lenting, Peter J.
    Denis, Cecile, V
    [J]. BLOOD, 2020, 136 (06) : 740 - 748
  • [7] Italian Association of Haemophilia Centres (AICE), PRINC TRATT AGG RACC
  • [8] Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
    Lenting, Peter J.
    Denis, Cecile V.
    Christophe, Olivier D.
    [J]. BLOOD, 2017, 130 (23) : 2463 - 2468
  • [9] Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
    Mahlangu, J.
    Oldenburg, J.
    Paz-Priel, I.
    Negrier, C.
    Niggli, M.
    Mancuso, M. E.
    Schmitt, C.
    Jimenez-Yuste, V.
    Kempton, C.
    Dhalluin, C.
    Callaghan, M. U.
    Bujan, W.
    Shima, M.
    Adamkewicz, J. I.
    Asikanius, E.
    Levy, G. G.
    Kruse-Jarres, R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (09) : 811 - 822
  • [10] Real-world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures
    McCary, Isabella
    Guelcher, Christine
    Kuhn, Jan
    Butler, Regina
    Massey, Gita
    Guerrera, Michael F.
    Ballester, Lance
    Raffini, Leslie
    [J]. HAEMOPHILIA, 2020, 26 (04) : 631 - 636